Drug Trial Radar · NCT05853354
Comparative Efficacy, Safety, PK, and Immunogenicity Study
Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
392
Planned (sponsor's estimate)
Start
Apr 5, 2023
Primary completion
Jul 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 60 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.
Conditions
- Osteoporosis, Postmenopausal
Interventions
DenosumabBiological
Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate equivalent efficacy between LY06006 and EU-Prolia, in terms of BMD in female participants with postmenopausal osteoporosis;Time frame: 12 months
- EU Marketing Authorization only: To demonstrate similar PD between LY06006 and EU-Prolia, in terms of the bone resorption marker sCTX in female participants with postmenopausal osteoporosisTime frame: 6 months
Locations
39 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Trials Management Services, LLC
Thousand Oaks, California
Indago Research and Health Center, Inc.
Hialeah, Florida
Valley Institute of Research
Fort Worth, Texas
MHAT Dr. Atanas Dafovski AD
Kardzhali, Bulgaria
Medical Centre Leo Clinic EOOD
Plovdiv, Bulgaria
Diagnostic-consultative center Ascendent EOOD
Sofia, Bulgaria
Medical Center Leo Clinic EOOD
Varna, Bulgaria
CCR Brno s.r.o.
Brno, Czechia
Synexus Prague
Prague, Czechia
Gifu Prefectural General Med C.
Gifu, Gihu, Japan
Asakawa Orthopedic Clinic
Chikugo, Hukuoka, Japan
Obase Hospital - Orthopedics
Miyako-gun, Hukuoka, Japan
Himeno Hospital
Yame-gun, Hukuoka, Japan
Marunouchi Hospital
Matsumoto-shi, Nagano, Japan
Nakamura Hospital
Beppu, Ôita, Japan
Nemoto Geka SeikeiGeka
Fujimi, Saitama, Japan
Kobayakawa Orthopedic Rheumatologic
Fukuroi, Shizuoka, Japan
Med Teda Ooimachi Orthopaedic
Shinagawa-ku, Tôkyô, Japan
Koenji Orthopedic Surgery
Shinagawa-ku, Tôkyô, Japan
Shimonoseki City Hospital
Shimonoseki, Yamaguchi, Japan
Centrum Medyczne Pratia Czestochowa
Częstochowa, Poland
Synexus Polska Sp. z o.o.
Częstochowa, Poland
Synexus Polska Sp. z o.o.
Gdansk, Poland
Centrum Medyczne Pratia Gdynia
Gdynia, Poland
Pratia Jelenia Gora
Jelenia Góra, Poland
Centrum Medyczne Pratia Katowice
Katowice, Poland
Pratia MCM Krakow
Krakow, Poland
Krakowskie Centrum Medyczne Sp.z o.o.
Krakow, Poland
Synexus Polska Sp. z. o.o.
Lodz, Poland
Centrum Medyczne AMED Oddzial w Lodzi
Lodz, Poland
Synexus Polska Sp. z o.o.
Poznan, Poland
FutureMeds Warszawa Centrum
Warsaw, Poland
Synexus Polska Sp. z o.o.
Warsaw, Poland
Centrum Medyczne AMED
Warsaw, Poland
Synexus Polska Sp. z o.o.
Wroclaw, Poland
FutureMeds Sp. z o.o.
Wroclaw, Poland
Centrum Medyczne Pratia Poznan
Skórzewo, Greater Poland Voivodeship, Poland
Centrum Medyczne Pratia Poznan
Skórzewo, Greater Poland Voivodeship, Poland
Synexus Polska Sp. z o.o.
Katowice, Silesian Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.